Abstract:
wherein the variables EG, EG1, SP1, SP2, SP3, Ar and BG are as defined herein. In another embodiment, the application discloses a method for forming a coating on a surface of a substrate using the surface binding compound of the Formula I or Formula II.
Abstract:
The invention provides a process for the preparation of a compound of Formula 1; comprising coupling a carboxylic acid of Formula 2; with an aniline of Formula 3; in the presence of a coupling agent.
Abstract:
The present invention provides prodrugs of GABA analogs, pharmaceutical compositions of prodrugs of GABA analogs and methods for making prodrugs of GABA analogs. The present invention also provides methods for using prodrugs of GABA analogs and methods for using phannaceutical compositions of prodrugs of GABA analogs for treating or preventing common diseases and/or disorders.
Abstract:
The present invention provides prodrugs of GABA analogs, pharmaceutical compositions of prodrugs of GABA analogs and methods for making prodrugs of GABA analogs. The present invention also provides methods for using prodrugs of GABA analogs and methods for using phannaceutical compositions of prodrugs of GABA analogs for treating or preventing common diseases and/or disorders.
Abstract:
Compounds of formula (I') wherein A, R1 to R3 and t are as defined in claims, exhibit COMT enzyme inhibiting activity so that they are useful as COMT inhibitors.
Abstract:
A process for the preparation of fluorinated dicarbonyl compounds of general formula (2), comprising reacting dicarbonyl compounds of general formula (1) with fluorine gas without any solvent in the presence of one or more acids selected from among trifluoromethanesulfonic acid, methanesulfonic acid, hydrofluoric acid, sulfuric acid, trifluoroacetic acid, boron trifluoride and sulfonated polymers wherein R?1, R2 and R3¿ are each hydrogen, alkyl or the like; and R?1a, R2a and R3a¿ are each the same as defined for R?1, R2 and R3¿, or alternatively when R?1, R2 and R3¿ are each hydrogen, the hydrogen may be replaced by fluorine, while when R?1, R2 and R3¿ are each optionally substituted alkyl, one or more hydrogen atoms on the α-position carbon atom to the CO-group may be replaced by fluorine. This process can give fluorinated dicarbonyl compounds in high yields and at high selectivity.
Abstract:
An analgesic agent is provided which has analgesic action and anti-inflammatory action without significant side effects found in conventional analgesics. The analgesic agent comprises as an active ingredient a cyclobutanedicarboxylic acid derivative, containing substituted diphenyl, represented by formula (I): wherein X 1 , X 2 , Y 1 , Y 2 , Z 1 , and Z 2 , which may be the same or different, each independently represent a hydrogen atom, hydroxyl, a halogen atom, alkyl, alkoxy, or a nitrogen-containing group; and R 1 and R 2 , which may be the same or different, each independently represent hydroxyl, a halogen atom, alkoxy, aryloxy, terpeneoxy, saccharide, or a nitrogen-containing group.